Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Immunic, Inc is a biotechnology business based in the US. Immunic shares (IMUX) are listed on the NASDAQ and all prices are listed in US Dollars. Immunic employs 26 staff and has a market cap (total outstanding shares value) of USD$351.6 million.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Mobile users
Latest market close | USD$17.62 |
---|---|
52-week range | USD$4.19 - USD$20.98 |
50-day moving average | USD$18.2182 |
200-day moving average | USD$16.7579 |
Wall St. target price | USD$60.86 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-11.305 |
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $17.62 from 2020-12-18
1 week (2021-01-07) | 1.38% |
---|---|
1 month (2020-12-17) | -3.93% |
3 months (2020-10-16) | -7.80% |
6 months (2020-07-16) | 39.29% |
1 year (2020-01-16) | 79.80% |
---|---|
2 years (2019-01-16) | 7,854.85% |
3 years (2018-01-16) | 214.64% |
5 years (2016-01-15) | 103.23% |
Gross profit TTM | USD$0 |
---|---|
Return on assets TTM | -26.89% |
Return on equity TTM | -36.3% |
Profit margin | 0% |
Book value | $7.861 |
Market capitalisation | USD$351.6 million |
TTM: trailing 12 months
There are currently 1.0 million Immunic shares held short by investors – that's known as Immunic's "short interest". This figure is 33.4% up from 785,535 last month.
There are a few different ways that this level of interest in shorting Immunic shares can be evaluated.
Immunic's "short interest ratio" (SIR) is the quantity of Immunic shares currently shorted divided by the average quantity of Immunic shares traded daily (recently around 403043.07692308). Immunic's SIR currently stands at 2.6. In other words for every 100,000 Immunic shares traded daily on the market, roughly 2600 shares are currently held short.
However Immunic's short interest can also be evaluated against the total number of Immunic shares, or, against the total number of tradable Immunic shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Immunic's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Immunic shares in existence, roughly 30 shares are currently held short) or 0.0501% of the tradable shares (for every 100,000 tradable Immunic shares, roughly 50 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Immunic.
Find out more about how you can short Immunic stock.
We're not expecting Immunic to pay a dividend over the next 12 months.
Immunic's shares were split on a 1:40 basis on 15 April 2019. So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Immunic shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for Immunic shares which in turn could have impacted Immunic's share price.
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn's disease, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme dihydroorotate dehydrogenase, which is in Phase 2 clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis, as well as in Phase 2 trial to treat Crohn's disease. The company is also developing IMU-935, an inverse agonist of RORgt; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
Everything we know about the Home Point Capital Inc IPO, plus information on how to buy in.
Everything we know about the ALFI INC IPO, plus information on how to buy in.
Steps to owning and managing CDAY, with 24-hour and historical pricing before you buy.
Steps to owning and managing CPF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CFFI, with 24-hour and historical pricing before you buy.
Steps to owning and managing BPY, with 24-hour and historical pricing before you buy.
Steps to owning and managing BANF, with 24-hour and historical pricing before you buy.
Steps to owning and managing AVDL, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEAM, with 24-hour and historical pricing before you buy.
Steps to owning and managing AUDC, with 24-hour and historical pricing before you buy.